KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Buildings (2016 - 2017)

Regeneron Pharmaceuticals (REGN) has disclosed Buildings for 6 consecutive years, with $1.4 billion as the latest value for Q4 2017.

  • For Q4 2017, Buildings rose 12.77% year-over-year to $1.4 billion; the TTM value through Dec 2017 reached $1.4 billion, up 12.77%, while the annual FY2017 figure was $1.4 billion, 12.77% up from the prior year.
  • Buildings hit $1.4 billion in Q4 2017 for Regeneron Pharmaceuticals, up from $1.3 billion in the prior quarter.
  • Across five years, Buildings topped out at $1.4 billion in Q4 2017 and bottomed at $343.4 million in Q4 2013.
  • Average Buildings over 5 years is $844.5 million, with a median of $760.5 million recorded in 2015.
  • Year-over-year, Buildings soared 90.61% in 2015 and then rose 12.77% in 2017.
  • Regeneron Pharmaceuticals' Buildings stood at $343.4 million in 2013, then increased by 16.2% to $399.0 million in 2014, then skyrocketed by 90.61% to $760.5 million in 2015, then surged by 68.08% to $1.3 billion in 2016, then grew by 12.77% to $1.4 billion in 2017.
  • According to Business Quant data, Buildings over the past three periods came in at $1.4 billion, $1.3 billion, and $760.5 million for Q4 2017, Q4 2016, and Q4 2015 respectively.